These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

595 related articles for article (PubMed ID: 25829424)

  • 1. HIF2α-Dependent Lipid Storage Promotes Endoplasmic Reticulum Homeostasis in Clear-Cell Renal Cell Carcinoma.
    Qiu B; Ackerman D; Sanchez DJ; Li B; Ochocki JD; Grazioli A; Bobrovnikova-Marjon E; Diehl JA; Keith B; Simon MC
    Cancer Discov; 2015 Jun; 5(6):652-67. PubMed ID: 25829424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Through a Clear Cell, Darkly: HIF2α/PLIN2-Maintained Fat Droplets Protect ccRCCs from ER Stress.
    Sim J; Johnson RS
    Cancer Discov; 2015 Jun; 5(6):584-5. PubMed ID: 26037916
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIF-2α/LINC02609/APOL1-mediated lipid storage promotes endoplasmic reticulum homeostasis and regulates tumor progression in clear-cell renal cell carcinoma.
    Xiao H; Qu Y; Li H; Zhang Y; Fei M; Liang C; Yang H; Zhang X
    J Exp Clin Cancer Res; 2024 Jan; 43(1):29. PubMed ID: 38263248
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Positive feedback regulation of lncRNA PVT1 and HIF2α contributes to clear cell renal cell carcinoma tumorigenesis and metastasis.
    Zhang MX; Zhang LZ; Fu LM; Yao HH; Tan L; Feng ZH; Li JY; Lu J; Pan YH; Shu GN; Li PJ; Tang YM; Liao ZY; Wei JH; Chen W; Guo JP; Luo JH; Chen ZH
    Oncogene; 2021 Sep; 40(37):5639-5650. PubMed ID: 34321604
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Opposite prognostic roles of HIF1α and HIF2α expressions in bone metastatic clear cell renal cell cancer.
    Szendrői A; Szász AM; Kardos M; Tőkés AM; Idan R; Szűcs M; Kulka J; Nyirády P; Szendrői M; Szállási Z; Győrffy B; Tímár J
    Oncotarget; 2016 Jul; 7(27):42086-42098. PubMed ID: 27244898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic Modulation of Clear-cell Renal Cell Carcinoma with Dichloroacetate, an Inhibitor of Pyruvate Dehydrogenase Kinase.
    Kinnaird A; Dromparis P; Saleme B; Gurtu V; Watson K; Paulin R; Zervopoulos S; Stenson T; Sutendra G; Pink DB; Carmine-Simmen K; Moore R; Lewis JD; Michelakis ED
    Eur Urol; 2016 Apr; 69(4):734-744. PubMed ID: 26433571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dysregulated D-dopachrome tautomerase, a hypoxia-inducible factor-dependent gene, cooperates with macrophage migration inhibitory factor in renal tumorigenesis.
    Pasupuleti V; Du W; Gupta Y; Yeh IJ; Montano M; Magi-Galuzzi C; Welford SM
    J Biol Chem; 2014 Feb; 289(6):3713-23. PubMed ID: 24356968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. USP37 promotes deubiquitination of HIF2α in kidney cancer.
    Hong K; Hu L; Liu X; Simon JM; Ptacek TS; Zheng X; Liao C; Baldwin AS; Zhang Q
    Proc Natl Acad Sci U S A; 2020 Jun; 117(23):13023-13032. PubMed ID: 32461361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loss of VHL and hypoxia provokes PAX2 up-regulation in clear cell renal cell carcinoma.
    Luu VD; Boysen G; Struckmann K; Casagrande S; von Teichman A; Wild PJ; Sulser T; Schraml P; Moch H
    Clin Cancer Res; 2009 May; 15(10):3297-304. PubMed ID: 19401348
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Restricted expression of miR-30c-2-3p and miR-30a-3p in clear cell renal cell carcinomas enhances HIF2α activity.
    Mathew LK; Lee SS; Skuli N; Rao S; Keith B; Nathanson KL; Lal P; Simon MC
    Cancer Discov; 2014 Jan; 4(1):53-60. PubMed ID: 24189146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FTY720 (Fingolimod) Inhibits HIF1 and HIF2 Signaling, Promotes Vascular Remodeling, and Chemosensitizes in Renal Cell Carcinoma Animal Model.
    Gstalder C; Ader I; Cuvillier O
    Mol Cancer Ther; 2016 Oct; 15(10):2465-2474. PubMed ID: 27507852
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of HIF1α in renal cell carcinoma tumorigenesis.
    Gudas LJ; Fu L; Minton DR; Mongan NP; Nanus DM
    J Mol Med (Berl); 2014 Aug; 92(8):825-36. PubMed ID: 24916472
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIF2α acts as an mTORC1 activator through the amino acid carrier SLC7A5.
    Elorza A; Soro-Arnáiz I; Meléndez-Rodríguez F; Rodríguez-Vaello V; Marsboom G; de Cárcer G; Acosta-Iborra B; Albacete-Albacete L; Ordóñez A; Serrano-Oviedo L; Giménez-Bachs JM; Vara-Vega A; Salinas A; Sánchez-Prieto R; Martín del Río R; Sánchez-Madrid F; Malumbres M; Landázuri MO; Aragonés J
    Mol Cell; 2012 Dec; 48(5):681-91. PubMed ID: 23103253
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Formation of Renal Cysts and Tumors in Vhl/Trp53-Deficient Mice Requires HIF1α and HIF2α.
    Schönenberger D; Harlander S; Rajski M; Jacobs RA; Lundby AK; Adlesic M; Hejhal T; Wild PJ; Lundby C; Frew IJ
    Cancer Res; 2016 Apr; 76(7):2025-36. PubMed ID: 26759234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overexpression of PLIN2 is a prognostic marker and attenuates tumor progression in clear cell renal cell carcinoma.
    Cao Q; Ruan H; Wang K; Song Z; Bao L; Xu T; Xiao H; Wang C; Cheng G; Tong J; Meng X; Liu D; Yang H; Chen K; Zhang X
    Int J Oncol; 2018 Jul; 53(1):137-147. PubMed ID: 29749470
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD70-Targeted Micelles Enhance HIF2α siRNA Delivery and Inhibit Oncogenic Functions in Patient-Derived Clear Cell Renal Carcinoma Cells.
    Trac N; Oh HS; Jones LI; Caliliw R; Ohtake S; Shuch B; Chung EJ
    Molecules; 2022 Dec; 27(23):. PubMed ID: 36500549
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NUPR1 is a novel potential biomarker and confers resistance to sorafenib in clear cell renal cell carcinoma by increasing stemness and targeting the PTEN/AKT/mTOR pathway.
    He W; Cheng F; Zheng B; Wang J; Zhao G; Yao Z; Zhang T
    Aging (Albany NY); 2021 May; 13(10):14015-14038. PubMed ID: 34030133
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low DAPK1 expression correlates with poor prognosis and sunitinib resistance in clear cell renal cell carcinoma.
    Song Z; Li Z; Han W; Zhu C; Lou N; Li X; Luo G; Peng S; Li G; Zhao Y; Guo Y
    Aging (Albany NY); 2020 Nov; 13(2):1842-1858. PubMed ID: 33201837
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PHGDH as a Key Enzyme for Serine Biosynthesis in HIF2α-Targeting Therapy for Renal Cell Carcinoma.
    Yoshino H; Nohata N; Miyamoto K; Yonemori M; Sakaguchi T; Sugita S; Itesako T; Kofuji S; Nakagawa M; Dahiya R; Enokida H
    Cancer Res; 2017 Nov; 77(22):6321-6329. PubMed ID: 28951458
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Junction plakoglobin regulates and destabilizes HIF2α to inhibit tumorigenesis of renal cell carcinoma.
    Chen K; Zeng J; Sun Y; Ouyang W; Yu G; Zhou H; Zhang Y; Yao W; Xiao W; Hu J; Xing J; Xiao K; Wu L; Chen Z; Ye Z; Xu H
    Cancer Commun (Lond); 2021 Apr; 41(4):316-332. PubMed ID: 33591636
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.